NEI Research News

New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis pigmentosa. No therapy exists for this rare inherited disease, which starts affecting vision from childhood.

New CRISPR gene editing approach may also be useful for treating other inherited diseases, such as cystic fibrosis and familial hypercholesterolemia

Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa.

Northwestern study finds ‘alarming’ disparities — lack of glaucoma care can lead to blindness.

Researchers create a new robotic surgery device that aims to give surgeons “superhuman” hands, accounting for patients’ breathing and eye movements, along with their own involuntary hand tremors, while they work on retinal tissues.

New findings from a National Eye Institute-led study add a twist on how a widely used cell death marker, annexin-V, can be interpreted in the lab and the clinic for tracking retinal cell death in eye diseases such as glaucoma.

ARPA-H announced the teams to receive awards from its Transplantation of Human Eye Allografts (THEA) program.

National Eye Institute-funded scientists using gene editing corrected a mutation in a mouse model of retinitis pigmentosa, an inherited blinding eye disorder. The gene editing strategy restored production of rhodopsin, and retinal function and structure

Research team has identified advanced preclinical candidates targeting the bisretinoid synthesis pathway, which could help treat macular degeneration and Stargardt disease.

New data demonstrate how social determinants of health can fuel disparities in monitoring for diabetic retinopathy for patients of different racial and ethnic groups.